ITAD for Pharmaceutical Companies

How an IT Asset Disposition program can help pharmaceutical companies comply with data security and environmental regulations.

Leading companies in the pharmaceutical industry are committed to ensuring the safety and wellbeing of their patients, and this extends beyond the development and distribution of critical drugs and medicine. One critical aspect of this commitment is the proper disposal of IT assets, which can pose significant data security and environmental risks if not handled correctly.

IT asset disposition (ITAD) is the process of disposing of obsolete or no longer useful IT assets in a secure manner and environmentally responsible manner. This includes devices that may contain sensitive patient information or hazardous materials. Proper ITAD ensures that these assets are disposed of in a way that protects patient privacy and the environment, while also complying with relevant regulations including HIPAA, 21 CFR Part 11, and GDPR. When these devices reach the end of their useful life, companies must ensure that the data they contain is securely erased or destroyed to prevent unauthorized access or data breaches.

With this combination of regulatory complexity and risk, it’s essential to choose an ITAD provider like Ingram Micro. Our global reach, experience, processes, and certifications help ensure an effective and secure asset EOL program.

In addition, Ingram Micro’s ITAD services is e-Stewards certified and therefore adheres to the most stringent downstream processes for the responsible recycling of electronic waste, further promoting sustainability programs and reducing the negative impact e-waste has on the environment.

Equipment that may contain sensitive information

  • PCs, Laptops, and Tablets
  • Servers and Storage
  • Smart phones
  • Copiers, printers, and fax machines
  • Network equipment
  • Hard drives and USB drives
Industry Spotlight - Pharmaceutical
Data Breach Facts

According to the Cost of a Data Breach Report 2022, conducted by the Ponemon Institute, the average cost of a data breach in the U.S. was $9.44 million, up 4.3% from 2022. Additionally, the average cost for a data breach among pharmaceutical companies was 5.01 million, the third highest among industries tracked.

Complete the form below to have someone reach out to you and discuss our lifecycle service offerings.